AbbVie stock: Etentamig filing adds an oncology milestone
Published on 10/29/2026 at 17:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline milestone and market context
- AbbVie submitted a U.S. biologics license application for etentamig for adults with relapsed or refractory multiple myeloma.
- The Phase 3 CERVINO study reported a 74.00 percent overall response rate versus 45.70 percent for standard therapies.
- The filing remains subject to FDA review, while infections and other safety outcomes remain relevant to the commercial assessment.
AbbVie submitted a biologics license application for etentamig to the U.S. Food and Drug Administration on October 27, 2026, according to GuruFocus News. The application covers adults with relapsed or refractory multiple myeloma and adds a regulatory milestone to AbbVie's oncology pipeline.
What has changed since the last report
The relevant own report on October 28 described the filing and its supporting CERVINO data, while quoting AbbVie stock at EUR 256.55 at 10:41 a.m. CET. The current Lang & Schwarz quote is EUR 259.90 on October 29, 2026, at 16:30:37 Berlin time. That is an increase of 1.31 percent from the earlier quoted level, which is the qualifying change for this second main-value report and is separate from the Xetra day comparison.
Clinical evidence and remaining risks
CERVINO enrolled 393 patients who had received at least two prior lines of treatment. Etentamig achieved a 74.00 percent overall response rate, compared with 45.70 percent for investigator-selected standard therapies, and reduced the risk of disease progression or death by 60.00 percent versus standard therapy.
The application is not a marketing approval. The FDA must review the submission before etentamig can be commercialized. The study also reported grade 3 or 4 infections in 27.70 percent of etentamig patients versus 19.20 percent in the comparison group, while treatment-related discontinuations were 3.60 percent versus 14.00 percent.
Investor context
AbbVie operates in healthcare and drug manufacturing, with commercial activities across immunology, neuroscience, oncology and other therapeutic areas. The company is scheduled to report third-quarter results on October 30, 2026, making the regulatory filing an additional pipeline item ahead of the earnings event.
The current Lang & Schwarz quote of EUR 259.90 is 1.29 percent above the verified Xetra close of EUR 256.60 from October 28, 2026. The real-time quote of AbbVie Inc. stock provides the continuously updated market view.
The broader market context is available through the S&P 500 market reports.
More news and analyses on AbbVie Inc. stock
AbbVie Inc. stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Sector / industry: Healthcare / Drug Manufacturers - General
- Lang & Schwarz price: EUR 259.90 on October 29, 2026 at 16:30:37 Berlin time
- Change versus prior own report: plus 1.31 percent from EUR 256.55 on October 28, 2026 at 10:41 a.m. CET
- Change versus Xetra: plus 1.29 percent versus the October 28, 2026 close of EUR 256.60
